• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Dysregulation of the TOX-RUNX3 pathway in cutaneous T-cell lymphoma.
Authors: Dulmage BO, Akilov O, Vu JR, Falo LD, Geskin LJ Abstract Studies have examined gene expression changes in Sézary syndrome (SS), but disease pathogenesis remains largely unknown, and diagnosis and treatment are difficult. TOX is a transcription factor involved in CD4+ T-cell development with downstream effects on RUNX3, a known tumor suppressor gene. We sought to identify genes involved in SS disease pathogenesis with the potential to enable diagnosis and treatment. We utilized previously reported transcriptome sequencing data to construct a list of candidate genes, which was narrowed using pathway analysi...
Source: Oncotarget - May 30, 2019 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

STAT5 induces miR-21 expression in cutaneous T cell lymphoma.
In conclusion, we provide first evidence that miR-21 is expressed in situ in CTCL skin lesions, induced by IL-2 and IL-15 cytokines, and is regulated by STAT5 in malignant T cells. Thus, our data provide novel evidence for a pathological role of IL-2Rg cytokines in promoting expression of the oncogenic miR-21 in CTCL. PMID: 27329723 [PubMed - as supplied by publisher]
Source: Oncotarget - June 23, 2016 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

STAT3/5 dependent IL-9 overexpression contributes to neoplastic cell survival in mycosis fungoides.
CONCLUSIONS: Our results suggest that IL-9 and its regulators are promising new targets for therapy development in MF. PMID: 26851186 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - February 5, 2016 Category: Cancer & Oncology Authors: Vieyra-Garcia PA, Wei T, Gram Naym D, Fredholm S, Fink-Puches R, Cerroni L, Odum N, O'Malley JT, Gniadecki R, Wolf P Tags: Clin Cancer Res Source Type: research

Dysregulation of the TOX-RUNX3 pathway in cutaneous T-cell lymphoma.
Authors: Dulmage BO, Akilov O, Vu JR, Falo LD, Geskin LJ Abstract Studies have examined gene expression changes in Sézary syndrome (SS), but disease pathogenesis remains largely unknown, and diagnosis and treatment are difficult. TOX is a transcription factor involved in CD4+ T-cell development with downstream effects on RUNX3, a known tumor suppressor gene. We sought to identify genes involved in SS disease pathogenesis with the potential to enable diagnosis and treatment. We utilized previously reported transcriptome sequencing data to construct a list of candidate genes, which was narrowed using pathway analysi...
Source: Oncotarget - November 14, 2015 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Ectopic expression of a novel CD22 splice-variant regulates survival and proliferation in malignant T cells from cutaneous T cell lymphoma (CTCL) patients.
In conclusion, we provide the first evidence for an ectopic expression of CD22 and a novel splice variant regulating malignant proliferation and survival in CTCL. Analysis of expression and function of CD22 in cutaneous lymphomas may form the basis for development of novel targeted therapies for our patients. PMID: 25957418 [PubMed - as supplied by publisher]
Source: Oncotarget - May 11, 2015 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Abstract 5112: Histone deacetylase and proteasome inhibitors synergistically induce apoptosis in colon cancer, multiple myeloma and CTCL cells through induction of the immediate early genes ATF3 and JUN
Conclusions: This study provides insight into the mechanistic basis by which combination treatment with HDAC and proteasome inhibitors synergistically induces apoptosis in tumour cells. Citation Format: Janson WT Tse, Anderly C. Chueh, Ian Y. Luk, Fiona Chionh, Yvonne Yeung, Georgia A. Corner, Dominic CH Ng, Hoanh Tran, Amardeep S. Dhillon, John M. Mariadason. Histone deacetylase and proteasome inhibitors synergistically induce apoptosis in colon cancer, multiple myeloma and CTCL cells through induction of the immediate early genes ATF3 and JUN. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Associ...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Tse, J. W., Chueh, A. C., Luk, I. Y., Chionh, F., Yeung, Y., Corner, G. A., Ng, D. C., Tran, H., Dhillon, A. S., Mariadason, J. M. Tags: Molecular and Cellular Biology Source Type: research

Regulation of cellular processes by interleukin‐16 in homeostasis and cancer
This article will review the cellular process for generating IL‐16, the biological activities for both the pro‐ and secreted forms of the protein, and then the mechanism by which these forms contribute to cancer progression. As a soluble cytokine the ability to reduce or eliminate IL‐16 synthesis through siRNA approaches or bioactivity through the use of neutralizing antibody treatment may represent a novel therapeutic approach. J. Cell. Physiol. © 2013 Wiley Periodicals, Inc.
Source: Journal of Cellular Physiology - July 29, 2013 Category: Cytology Authors: Jillian Richmond, Marina Tuzova, William Cruikshank, David Center Tags: Mini‐Review Source Type: research